Organization Profile

Related Organization(s)

You just read:

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

News provided by

Eli Lilly and Company

Jun 09, 2016, 06:45 ET